The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis (original) (raw)
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Andrzej Pilc
Clinical Rheumatology, 2013
View PDFchevron_right
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Alan Kivitz
The Journal of Rheumatology, 2014
View PDFchevron_right
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
Valderilio F Azevedo
Rheumatology and Therapy, 2021
View PDFchevron_right
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Cristiano Moura
Arthritis research & therapy, 2018
View PDFchevron_right
Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
Joel Kremer
Arthritis Care & Research, 2017
View PDFchevron_right
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
Joel Kremer
International Journal of Rheumatic Diseases, 2016
View PDFchevron_right
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
Valderilio F Azevedo
Rheumatology and Therapy
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies
Erika García, Karina Santana, Daniel Xavier Xibille Friedmann
Reumatología Clínica, 2017
View PDFchevron_right
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Joel Kremer
New England Journal of Medicine, 2012
View PDFchevron_right
European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
Maria Kózka
Therapeutics and clinical risk management, 2018
View PDFchevron_right
Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Alan Worsley, Ying He
BMC Musculoskeletal Disorders, 2013
View PDFchevron_right
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
vibeke strand
Arthritis Research & Therapy, 2015
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies
Erika García, Karina Santana, Daniel Xavier Xibille Friedmann
Reumatología Clínica, 2017
View PDFchevron_right
Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
Nandini Kishore
Journal of Pharmacology and Experimental Therapeutics, 2013
View PDFchevron_right
Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial
vibeke strand
Arthritis Care & Research, 2016
View PDFchevron_right
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
J. Gomez-Reino
Current Therapeutic Research, 2020
View PDFchevron_right
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Valderilio F Azevedo
The New England journal of medicine, 2017
View PDFchevron_right
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Mark Genovese
Arthritis research & therapy, 2016
View PDFchevron_right
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study
Joel Kremer
2019
View PDFchevron_right
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis
Alomgir Hossain
The Cochrane database of systematic reviews, 2017
View PDFchevron_right
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Jamie Geier
Annals of the rheumatic diseases, 2017
View PDFchevron_right
Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
Kay Myint, Soe Moe
ISRN Rheumatology, 2013
View PDFchevron_right
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
Joseph Cappelleri
RMD Open, 2021
View PDFchevron_right
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Irmgadt Sariego
Lancet (London, England), 2017
View PDFchevron_right
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
vibeke strand
Rheumatology and therapy, 2018
View PDFchevron_right
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
Mark Genovese
Annals of Internal Medicine, 2013
View PDFchevron_right
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
J. Gomez-Reino
Arthritis & Rheumatism, 2012
View PDFchevron_right